Market Cap (In USD)
689.01 Million
Revenue (In USD)
2.82 Million
Net Income (In USD)
-43.55 Million
Avg. Volume
252.76 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 7.75-33.77
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US2528281080
- CUSIP
- 252828108
- CIK
- 1690585
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Marino Garcia M.B.A.
- Employee Count
- -
- Website
- https://dianthustx.com
- Ipo Date
- 2018-06-21
- Details
- Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
More Stocks
-
MGMNFMagna Mining Inc.
MGMNF
-
035000GIIR Inc.
035000
-
BMW
-
UTIAMC
-
TVSMOTORTVS Motor Company Limited
TVSMOTOR
-
OXBC
-
AE
-
FOOT-PREFFootway Group AB (publ)
FOOT-PREF